LEAP-009: Phase 2 study of lenvatinib with or without pembrolizumab vs chemotherapy for the treatment of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) upon progression after platinum and immunotherapy (PD-1/PD-L1 inhibition)
Authors
Harrington, K. J.Kim, H. R.
Salas, S.
Oliva, M.
Metcalf, Robert
Bernsdorf, M.
Kim, J. W.
Cohen, E. E. W.
Siu, L.
Rischin, D.
Licitra, L.
Vermorken, J.
Le, Q.
Tahara, M.
Machiels, J. P.
O'Hara, K.
Pathiraja, K.
Gumuscu, B.
Bidadi, B.
Burtness, B.
Bowers, E.
Affiliation
Institute of Cancer Research and The Royal Marsden NHS FoundationTrust,National Institute for Health and Care Research Biomedical Research Centre, LondonIssue Date
2022